Quent Capital LLC Has $173,000 Stake in 10x Genomics, Inc. (NASDAQ:TXG)

Quent Capital LLC grew its position in 10x Genomics, Inc. (NASDAQ:TXG) by 83.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,916 shares of the company’s stock after purchasing an additional 4,068 shares during the quarter. Quent Capital LLC’s holdings in 10x Genomics were worth $173,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in TXG. Assenagon Asset Management S.A. acquired a new stake in 10x Genomics during the fourth quarter worth approximately $984,000. UMB Bank n.a. grew its position in 10x Genomics by 51.6% during the fourth quarter. UMB Bank n.a. now owns 782 shares of the company’s stock worth $44,000 after buying an additional 266 shares in the last quarter. Arizona State Retirement System lifted its stake in 10x Genomics by 3.4% during the fourth quarter. Arizona State Retirement System now owns 24,562 shares of the company’s stock worth $1,374,000 after purchasing an additional 813 shares during the last quarter. Bleakley Financial Group LLC bought a new stake in 10x Genomics during the fourth quarter worth $234,000. Finally, Cerity Partners LLC bought a new stake in 10x Genomics during the fourth quarter worth $811,000. Institutional investors and hedge funds own 84.68% of the company’s stock.

Insiders Place Their Bets

In other news, insider Benjamin J. Hindson sold 4,087 shares of the firm’s stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $24.30, for a total value of $99,314.10. Following the completion of the sale, the insider now directly owns 350,055 shares in the company, valued at approximately $8,506,336.50. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other news, CFO Justin J. Mcanear sold 2,936 shares of the firm’s stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $24.30, for a total value of $71,344.80. Following the completion of the sale, the chief financial officer now directly owns 146,203 shares in the company, valued at approximately $3,552,732.90. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Benjamin J. Hindson sold 4,087 shares of the firm’s stock in a transaction dated Wednesday, May 22nd. The shares were sold at an average price of $24.30, for a total value of $99,314.10. Following the completion of the sale, the insider now owns 350,055 shares of the company’s stock, valued at $8,506,336.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,900 shares of company stock worth $289,170. Company insiders own 10.03% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Guggenheim restated a “neutral” rating on shares of 10x Genomics in a research note on Tuesday, June 25th. Bank of America cut their target price on 10x Genomics from $36.00 to $25.00 and set a “neutral” rating for the company in a research note on Thursday, July 18th. Deutsche Bank Aktiengesellschaft cut 10x Genomics from a “buy” rating to a “hold” rating and cut their target price for the stock from $55.00 to $25.00 in a research note on Wednesday, July 10th. Stifel Nicolaus cut their target price on 10x Genomics from $53.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, July 16th. Finally, UBS Group dropped their price target on 10x Genomics from $52.00 to $30.00 and set a “neutral” rating for the company in a research note on Wednesday, May 1st. One analyst has rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $33.31.

10x Genomics Stock Up 2.9 %

10x Genomics stock traded up $0.54 during trading hours on Tuesday, reaching $18.87. 1,246,205 shares of the company’s stock were exchanged, compared to its average volume of 1,657,819. The firm’s 50 day simple moving average is $19.76 and its 200 day simple moving average is $30.70. 10x Genomics, Inc. has a twelve month low of $15.28 and a twelve month high of $57.90. The firm has a market capitalization of $2.25 billion, a PE ratio of -8.48 and a beta of 1.84.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.